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Intracardiac Thrombosis Involving All Four Cardiac Chambers 
after Extracardiac Membranous Oxygenation 
Associated with MTHFR Mutations
Bong Jun Kim, M.D.1, Seung Hwan Song, M.D.1, Yu Rim Shin, M.D.1, Han Ki Park, M.D.1, 
Young Hwan Park, M.D.1, Hong Ju Shin, M.D.1,2
A 4-month-old boy diagnosed with acute myocarditis was treated with extracorporeal membrane oxygenation (ECMO). 
Follow-up echocardiography eight hours after ECMO revealed intracardiac thrombosis involving all four heart cham-
bers. Because of the high risk of systemic embolization due to a pedunculated thrombus of the aortic valve, we 
performed an emergency thrombectomy. After the operation, the patient had a minor neurologic sequela of left up-
per arm hypertonia, which had almost disappeared at the last outpatient clinic two months later. He was diagnosed 
with a major mutation in MTHFR (methylenetetrahydrofolate reductase), which is related to thrombosis.
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CASE REPORT
A 4-month-old boy was referred to Severance Cardiovascu-
lar Hospital for suspicion of myocarditis. His body weight was 
7 kg and his medical history was unremarkable except a fever 
that had begun 7 days previously. A chest X-ray showed car-
diomegaly (cardiothoracic ratio 0.59). Electrocardiography re-
vealed sinus tachycardia with a heart rate of 247/min. 
Echocardiography showed a left ventricular ejection fraction 
of 25% with inotropic support including dopamine and dobut-
amine, and bi-ventricular enlargement was noted. Initial labo-
ratory tests revealed elevated levels of cardiac enzymes 
(creatine kinase–myocardial band was 39.1 ng/mL and tropo-
nin-T was 0.054 ng/mL), but normal levels of inflammation 
markers (C-reactive protein was 1.7 mg/L). The N-terminal 
pro-brain natriuretic peptide level was elevated above 35,000 
pg/mL. As we suspected myocarditis, we decided to apply ex-
tracorporeal membrane oxygenation (ECMO). Venoarterial 
ECMO was instituted to the right internal carotid artery and 
the right internal jugular vein after infusion of 350 units of 
heparin. After ECMO insertion, the flow rate suddenly drop-
ped from 0.5 to 0.1 L/min for 15 minutes. During that time, 
the mean arterial pressure was maintained below 30 mmHg and 
the pulse pressure disappeared, so we started an epinephrine 
infusion. After the infusion of epinephrine, the mean arterial 
pressure increased gradually to above 60 mmHg and a pulse 
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Fig. 1. (A) Transthoracic echocardio-
graphy apical four chamber view de-
monstrating thrombi in all four cham-
bers of the heart and the para-
sternal long axis view. (B) Transtho-
racic echocardiography demonstrating 
thrombus in the RA and RV. RV, 
right ventricle; LV, left ventricle; RA, 
right atrium; LA, left atrium.
pressure appeared. The ECMO flow rate increased and was 
maintained at 0.5 L/min with an activated clotting time of 
more than 170 seconds. However, follow-up echocardiography 
after eight hours revealed intracardiac thrombosis involving all 
four chambers (Fig. 1A, B and Videos 1, 2). Therefore, we de-
cided to perform an emergency thrombectomy. After median 
sternotomy, cardiopulmonary bypass via the ascending aorta 
and inferior vena cava was prepared, and then ECMO was 
stopped. Under routine cardiopulmonary bypass, an additional 
cannula through the superior vena cava was inserted. After 
aortic cross-clamping, a right atriotomy and atrial septectomy 
were performed for exposure of the left side. Thrombectomy 
of both the atrium and ventricle was done and an aortotomy 
was performed to inspect the lower portion of the aortic 
valve. A muscle biopsy of the right ventricular septal wall 
was also performed. The thrombus was fresh and red. An at-
rial septectomy of 8 mm was allowed to remain for left side 
decompression. After ensuring that there was no intracardiac 
thrombus via epicardial echocardiography, the ECMO circuit 
was changed and restarted with a flow of 0.5 L/min. The car-
diopulmonary bypass time was 91 minutes, and the aortic 
cross-clamping time was 46 minutes. The postoperative course 
was smooth except for a hematoma evacuation procedure one 
day after the operation. Heart function recovery was rapid and 
the patient was weaned from ECMO two days after surgery. 
The duration of ECMO was 60 hours. On postoperative day 4, 
we investigated a focal seizure. A brain magnetic resonance 
imaging study showed multifocal diffusion restriction in the 
bilateral cerebral hemispheres and left cerebellum. Thus, we 
started aspirin and a direct thrombin inhibitor, argatroban, due 
to the possibility of heparin-induced thrombocytopenia. The 
duration of mechanical ventilation and intensive care unit 
(ICU) stay was 11 days and 17 days, respectively. During the 
stay in the ICU, arrhythmic medication including flecainide, 
amiodarone, and digoxin was prescribed for intermittent ta-
chyarrhythmia, which usually presented as paroxysmal supra-
ventricular tachycardia. After transfer to the general ward, the 
patient was treated for left arm hypertonia and delayed devel-
opment with the help of the department of rehabilitation. 
During the hospital stay, the patient was diagnosed with a 
major heterozygous mutation in the MTHFR (methylenetetra-
hydrofolate reductase gene); however, the patient had a normal 
homocysteine level for an infant (2.91 μmol/L). Immunoassays 
for anti-platelet factor 4/heparin antibodies were negative. At 
postoperative day 23, a newly developed 5-mm thrombus was 
observed in the chordae of the tricuspid valve and the left 
pulmonary drainage site. Thus, we switched to warfarin as 
anticoagulation treatment to maintain an international normal-
ized ratio of 2.0. He was discharged home with improvement 
of left arm motion. A follow-up echocardiography 11 months 
later showed a normal ejection fraction of 65% without 
thrombus.
DISCUSSION
During ECMO support, appropriate anticoagulation that 
balances hemorrhage and thrombosis is necessary. When 
thrombosis events occur, prompt recognition and treatment is 
important to prevent further sequelae including cerebrovascular 
thrombosis, pulmonary injury, and renal thrombosis. The most 
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appropriate management of intracardiac thrombi in pediatric 
patients has not been well established.
Treatment options include either surgical thrombectomy or 
medical thrombolysis. The choice of treatment depends on the 
thrombus location (right chamber versus left chamber), size, 
response to previous therapy, and other risk factors. 
Right-chamber intracardiac thrombi are much more common 
and are usually treated with anticoagulation therapy. Medical 
treatment using tissue-type plasminogen activator for intra-
cardiac and aortic thrombi has been reported [1,2].
Left-chamber cardiac thrombosis is rare and should be 
treated more aggressively. Surgery is often undertaken to pre-
vent catastrophic systemic thromboembolic events, particularly 
when the thrombus is large. According to an analysis of 40 
intracardiac thrombi from Texas, 18 of the 40 thrombi were 
found in the left chamber. Two patients with a total of four 
intracardiac thrombi were lost to follow-up after the initial 
echocardiograms, and unfortunately, their data were not 
shown in the published report [3]. Another paper from Korea 
reported that three of five intracardiac thrombi in children 
with dilated cardiomyopathy were found in the left ventricle. 
They were treated with heparin and warfarin, except one 
case, which was treated by thrombectomy [4].
To our knowledge, this is the first report describing the di-
agnosis and treatment of intracardiac thrombi appearing in all 
four chambers. The possible mechanisms are assumed to be 
related to MTHFR mutations, which impair the patient's abil-
ity to metabolize homocysteine. This defective gene leads to 
elevated levels of homocysteine, resulting in an increased risk 
for coronary artery disease or venous thrombosis. Taking fol-
ic acid and vitamin B6 can lower elevated homocysteine lev-
els [5].
Because of the high risk of systemic embolization due to a 
pedunculated aortic valve thrombus, we performed an emer-
gency thrombectomy. After the operation, the patient had a 
minor neurologic sequela of left upper arm hypertonia, which 
had almost disappeared by the time of the last outpatient 
clinic two months later. If the operation had been delayed, 
the patient’s clinical status after the systemic embolization 
would have been fatal. The timely operation saved the pa-
tient’s life, which had been threatened by thrombi in four 
chambers after ECMO support.
In conclusion, we report an intracardiac thrombus involving 
four chambers after ECMO support and successful surgical 
treatment.
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SUPPLEMENTARY MATERIALS
Supplementary materials can be found via http://dx.do-
i.org/10.5090/kjtcs.2016.49.3.207. Video 1. Transthoracic echo-
cardiography apical four chamber view demonstrating throm-
bus in all four chambers of heart.
Supplementary materials can be found via http://dx.do-
i.org/10.5090/kjtcs.2016.49.3.207. Video 2. Transthoracic echo-
cardiography parasternal long axis view demonstrating thro-
mbus in left atrium and left ventricle attached to a mitral and 
aortic valve.
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